Clinical trials: System Lupus Erythematosus
Systemic Lupus Erythematosus
Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region
Lupus Low Disease Activity State (LLDAS) study is an international, multi-centre prospective study, developed by the Asia Pacific Lupus Collaboration (APLC) to investigate whether the attainment of LLDAS is associated with…
- Trial name
- APLCLLDAS (NCT03138941)
- Where
- 20 sites in Australia, China and 9 more
- Volunteers
- 5,000 people
- Sponsor
- Monash University
Systemic Lupus Erythematosus
Vitamin D3 Treatment in Pediatric Systemic Lupus Erythematosus
The primary objective of this study is to evaluate the effects of 18 weeks of high-dose vitamin D3 supplementation compared with standard-dose vitamin D3 supplementation on immune function, glucose homeostasis, and bone…
- Trial name
- NCT01709474
- Testing
- Vitamin D3 6000 IU, Vitamin D3 400 IU
- Where
- 13 sites in United States
- Volunteers
- 7 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Systemic Lupus Erythematosus
Effect of Curcumin on Systemic Lupus Erythematosus
The purpose of this investigator initiated study is to determine the efficacy of curcumin on disease activity of subjects with systemic lupus erythematous.
- Trial name
- NCT03953261
- Testing
- Curcumin supplement
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Loma Linda University
Lupus Nephritis, Lupus Nephritis - WHO Class III
KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis
- Conditions
- Lupus Nephritis, Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV
- Trial name
- NCT06342960
- Testing
- KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen
- Where
- 6 sites in Germany
- Volunteers
- 2 people
- Sponsor
- Kyverna Therapeutics
Inflammatory Disease, Rheumatoid Arthritis
Vaccination Perception in Inflammatory Conditions - Flu, Pneumonia and COVID-19
People with inflammatory diseases are often treated with medications that act to suppress the immune-system, increasing the risk of catching infections.
- Conditions
- Inflammatory Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Systemic Lupus Erythematosus
- Trial name
- OPINION (NCT05115370)
- Testing
- Semi-structured qualitative interview
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Osteoporosis, Juvenile Rheumatoid Arthritis
Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders
The purpose of this study is to evaluate denosumab as a novel treatment for bone loss in children treated with glucocorticoids for rheumatic disorders.
- Conditions
- Osteoporosis, Juvenile Rheumatoid Arthritis, Dermatomyositis, Polyarthritis
- Trial name
- NCT02418273
- Testing
- denosumab
- Where
- United States
- Sponsor
- Indiana University
Systemic Lupus Erythematosus
Abnormalities of B Lymphocytes During Systemic Lupus
Previous experimental data strongly suggest that B lymphocytes have intrinsic abnormalities during lupus in mice spontaneously affected by the disease.
- Trial name
- NCT00401141
- Testing
- Blood samples
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Lupus Erythematosus, Systemic Lupus Erythematosus
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
SC291-102 is a Phase 1 study to evaluate SC291 safety and tolerability, preliminary clinical response, cellular kinetics and exploratory assessments for subjects with severe autoimmune diseases.
- Conditions
- Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- NCT06294236
- Testing
- SC291
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Sana Biotechnology
Juvenile Idiopathic Arthritis, Rheumatoid Arthritis
Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults
Population: Juvenile idiopathic arthritis (JIA), rheumatoid arthritis (RA) and seronegative / psoriatic / undifferentiated arthritis (UA), systemic lupus erythematosus (SLE) or diffuse systemic sclerosis dSS).
- Conditions
- Juvenile Idiopathic Arthritis, Rheumatoid Arthritis, Psoriatic Arthritis, Systemic Lupus Erythematosus
- Trial name
- NCT07000916
- Where
- Belgium
- Volunteers
- 1,000 people
- Sponsor
- Université Catholique de Louvain
Systemic Lupus Erythematosus
The Anifrolumab PRIM Program
Pregnancy and infant outcomes in anifrolumab exposed pregnancies using PRegnancy outcomes Intensive Monitoring (PRIM) data: The anifrolumab PRIM program
- Trial name
- PRIM (NCT06795893)
- Testing
- Anifrolumab
- Where
- Sweden
- Volunteers
- 240 people
- Sponsor
- AstraZeneca
Systemic Lupus Erythematosus
Cardiac and Laboratory Findings in Patients With Systemic Lupus Erythematosus
This study is designed to investigate the association of the clinical and laboratory parameters or data with the cardiac structural and functional abnormalities in systemic lupus erythematosus(SLE).
- Trial name
- NCT03179046
- Testing
- Laboratory tests and cardiac imaging
- Where
- Egypt
- Volunteers
- 36 people
- Sponsor
- Assiut University
Lupus, Lupus Arthritis
The Burden of Lupus in Canada From a Patient Perspective: A Canadian Real-World PROxy Study
This study aims to capture the Canadian patient experience, burden, barriers, and treatment preferences. The findings will generate real-world evidence to support patient-centered care and guide healthcare providers, researchers…
- Conditions
- Lupus, Lupus Arthritis, Lupus Arthritis, Systemic Lupus Erythematosus, Quality of Life (QOL)
- Trial name
- NCT07267091
- Testing
- No Intervention: Observational Cohort
- Where
- Canada
- Volunteers
- 88 people
- Sponsor
- PeriPharm
Systemic Lupus Erythematosus, Lupus Erythematosus
A Study of Imvotamab in Severe Systemic Lupus Erythematosus
The purpose of this study is to determine the safety and tolerability of imvotamab in patients with severe systemic lupus erythematosus who have failed prior therapies.
- Trial name
- NCT06041568
- Testing
- Imvotamab
- Where
- 10 sites in United States, Poland and 1 more
- Volunteers
- 17 people
- Sponsor
- IGM Biosciences, Inc.
Systemic Lupus Erythematosus
GADD34 and Type I IFN Response Genes in SLE
GADD34 (Growth Arrest and DNA Damage inducible-protein) is a regulatory subunit of PP1 (phosphatase 1) phosphatase which dephosphorylates eIF2alpha (eucaryotic initiation factor 2 alpha subunit), representing a negative feedback…
- Trial name
- GADD34-IFN (NCT03206359)
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Cutaneous Lupus Erythematosus-Systemic Lupus Erythematosus
Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion
Primary Objective: To investigate the efficacy on skin manifestation of 16 weeks treatment of once daily regimen of hydroxychloroquine sulphate (HCQ) in patients with cutaneous lupus erythematosus (CLE) and systemic lupus…
- Trial name
- NCT01551069
- Testing
- hydroxychloroquine (Z0188)
- Where
- 22 sites in Japan
- Volunteers
- 103 people
- Sponsor
- Sanofi
Systemic Lupus Erythematosus
Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment in Quiescent Systemic Lupus
Systemic Lupus (SLE) is a chronic disease for which long term treatments are warranted. The aim of this study was to study the possibility of corticosteroids interruption in patients with quiescent SLE treated since at least one…
- Trial name
- CORTICOLUP (NCT02558517)
- Testing
- prednisone discontinuation
- Where
- France
- Volunteers
- 136 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Systemic Lupus Erythematosus
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetic of TQB3702 Tablets in Healthy Adult Subjects
This is a phase I, randomized, double-blind, placebo-controlled, dose-escalating clinical study aimed at evaluating the safety of TQB3702 tablets following single and multiple doses administered to healthy subjects
- Trial name
- NCT06448273
- Testing
- TQB3702 tablets
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Lupus Nephritis
ACTHar in the Treatment of Lupus Nephritis
Systemic Lupus Erythematosus (SLE) is a disease in which the immune system attacks the healthy cells and tissues, causing inflammation that can damage organs in the body.
- Trial name
- ACTHar (NCT02226341)
- Testing
- CellCept, ACTHar gel
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Columbia University
Lupus Erythematosus, Systemic
Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE)
The purpose of this two-part multiple ascending dose study is to evaluate the safety and tolerability of multiple doses of MHS552 in adults with mild to moderately active Systemic Lupus Erythematosus (SLE).
- Trial name
- NCT05203419
- Testing
- MHS552
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus
Phase II/III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Mild to Moderate Systemic Lupus Erythematosus
OBJECTIVES: I. Evaluate the safety and efficacy of synthetic dehydroepiandrosterone (GL701) in women with prednisone-dependent systemic lupus erythematosus. II. Describe the pharmacokinetics of GL701.
- Trial name
- NCT00004795
- Testing
- dehydroepiandrosterone
- Volunteers
- 190 people
- Sponsor
- National Center for Research Resources (NCRR)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.